A London scientist is working on the world’s first oral insulin patch that could save diabetes patients from having to regularly inject the drug. Dr Hend Abdelhakim, an assistant professor at ...
Embecta announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan.
CEO Dev Kurdikar said the decision may “come as a surprise” as Embecta just received FDA clearance for a patch pump, but the ...
Get up to 30% off detailed market research reports-for a limited time only! The insulin patch pumps market size is expected to see rapid growth in the next few years. It will grow to $2.16 billion ...
Embecta Corp.'s Q4 results showed significant net income and EPS growth. Embecta also announced a restructuring plan. See why ...
we have decided to discontinue our insulin patch pump program and initiate an organizational restructuring plan. We believe this approach will streamline operations, reduce costs and enhance our ...
Never miss a trade again with the fastest news alerts in the world! This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday. Want ...
Embecta expects between $25 million and $30 million in pre-tax, cash charges for planned workforce reductions and other associated costs. Embecta expects between $35 million and $45 million in pre ...
Kurdikar, CEO of Embecta (EMBC) said, “As our stand-up work nears completion and following an in-depth review of our ...
The Becton, Dickinson and Company (NYSE:BDX) spin-off announced that it decided to discontinue its insulin patch pump program and plans to initiate a restructuring plan. In July, Embecta, a ...